21 completed, 5 unknown, 1 active not recruiting, 1 not yet recruiting. 13 Phase 3, 9 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 11, Unknown 2 |
| Phase 2 | 9 | Completed 5, Unknown 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Acute Pyelonephritis: new trials by email Literature Review of Acute Pyelonephritis trials Research Report on Acute Pyelonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis Ertapenem-zidebactam, Ceftazidime-Avibactam, Ertapenam-Zidebactam - Complicated Urinary Tract Infections(cUTI), Acute Pyelonephritis | Phase 2 | Not yet recruiting | Wockhardt | 279 | 2026-09-30 | 2026-09-24 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis Meropenem-Vaborbactam, Antibiotics - Acute Pyelonephritis, Complicated Urinary Tract Infection | Phase 2 | Active not recruiting | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | 66 | 2025-06-03 | 2026-09-10 |
| Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) WCK 4282 (FEP-TAZ) 4 g, Meropenem, ciprofloxacin 500 mg Optional Oral Switch - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Unknown | Wockhardt | 1004 | 2024-01-01 | 2023-07-17 |
| A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion - Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Spero Therapeutics | 1690 | 2023-12-21 | 2026-03-10 |
| NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification NGS-based assay for bacterial identification - Pneumonia, Acute Pyelonephritis | Completed | Hellenic Institute for the Study of Sepsis | 100 | 2023-11-16 | 2024-03-29 | |
| P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, BAT - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Meiji Seika Pharma Co., Ltd. | 126 | 2023-09-22 | 2026-04-13 |
| Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, imipenem/cilastatin - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Meiji Seika Pharma Co., Ltd. | 614 | 2023-05-23 | 2025-12-24 |
| Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Cefepime-zidebactam (FEP-ZID), Meropenem - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Wockhardt | 530 | 2022-08-28 | 2026-05-22 |
| Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections Meropenem- FL058, Piperacillin -tazobactam, Saline - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 2 | Unknown | Qilu Pharmaceutical Co., Ltd. | 150 | 2021-10-08 | 2021-09-29 |
| Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults Zavicefta, Ceftazidime-Avibactam, Best Available Treatment - Urinary Tract Infection, Acute Pyelonephritis | Phase 4 | Completed | Pfizer | 60 | 2021-08-26 | 2024-10-21 |
| Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children Dexamethasone Oral, Placebo - Urinary Tract Infections in Children, Dexamethasone | Phase 3 | Unknown | Hamad Medical Corporation | 120 | 2021-03-03 | 2023-07-25 |
| Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis Biomarkers for acute pyelonephritis - Acute Pyelonephritis | Completed | University of Southern Denmark | 229 | 2021-03-01 | 2022-09-14 | |
| Clinical Characteristics of Acutely Hospitalized Adults With Acute Pyelonephritis Clinical assessment - Acute Pyelonephritis | Completed | University of Southern Denmark | 966 | 2021-03-01 | 2022-09-14 | |
| Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis Acute Pyelonephritis, Complicated Urinary Tract Infection | Unknown | Thomayer University Hospital | 90 | 2020-06-24 | 2023-01-06 | |
| Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections Cefepime/VNRX-5133 (taniborbactam), Meropenem - Urinary Tract Infections, Acute Pyelonephritis | Phase 3 | Completed | Venatorx Pharmaceuticals, Inc. | 661 | 2019-08-07 | 2025-06-06 |
| Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) TBPM-PI-HBr, Ertapenem, Dummy Infusion - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Spero Therapeutics | 1372 | 2019-06-03 | 2022-07-25 |
| IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis Omadacycline, Levofloxacin - Acute Pyelonephritis | Phase 2 | Completed | Paratek Pharmaceuticals Inc | 201 | 2018-11-19 | 2020-07-07 |
| Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections Sulbactam-ETX2514, Placebo, Imipenem-cilastatin - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 2 | Completed | Entasis Therapeutics | 80 | 2018-01-17 | 2020-01-22 |
| Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections ZTI-01, Piperacillin-tazobactam - Urinary Tract Infection Symptomatic, Acute Pyelonephritis | Phase 2 / Phase 3 | Completed | Nabriva Therapeutics AG | 465 | 2016-04-01 | 2019-03-07 |
| A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) plazomicin, meropenem, levofloxacin (oral) - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Achaogen, Inc. | 609 | 2016-01-11 | 2018-08-23 |
Showing 20 of 29. Sign in to see all of them.
Urinary Tract Infections (8) · Bacteremia (4) · Bacterial Infections (4) · Pyelonephritis (3) · Emergencies (2) · Intraabdominal Infections (2) · Cholangitis (1) · Disease (1) · Escherichia coli Infections (1) · Glomerulonephritis (1) · Healthcare-Associated Pneumonia (1) · Infections (1) · Kidney Failure, Chronic (1) · Pneumonia (1) · Pneumonia, Ventilator-Associated (1)
Infections (11) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Male Urogenital Diseases (9) · Urogenital Diseases (9) · Urologic Diseases (9) · Bacterial Infections and Mycoses (8) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Bacterial Infections (4) · Disease Attributes (4) · Inflammation (4) · Kidney Diseases (4) · Nephritis (4) · Sepsis (4)
Meropenem (6) · Levofloxacin (4) · Cilastatin, Imipenem Drug Combination (3) · Piperacillin, Tazobactam Drug Combination (3) · Sodium Chloride (3) · meropenem and vaborbactam (3) · Anti-Bacterial Agents (2) · Ciprofloxacin (2) · Ertapenem (2) · avibactam, ceftazidime drug combination (2) · beta-Lactamase Inhibitors (2) · nacubactam (2) · plazomicin (2) · tebipenem (2) · vaborbactam (2)
Wockhardt (3) · Achaogen, Inc. (2) · Meiji Seika Pharma Co., Ltd. (2) · Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) (2) · Spero Therapeutics (2) · University of Southern Denmark (2) · Entasis Therapeutics (1) · Hamad Medical Corporation (1) · Hellenic Institute for the Study of Sepsis (1) · Institut Investigacio Sanitaria Pere Virgili (1) · Iterum Therapeutics, International Limited (1) · Mahidol University (1) · Melinta Therapeutics, Inc. (1) · MerLion Pharmaceuticals GmbH (1) · Nabriva Therapeutics AG (1)
Bulgaria (9) · United States (9) · Greece (8) · Georgia (7) · Latvia (7) · Slovakia (7) · Czechia (6) · Poland (6) · China (5) · Croatia (5) · Estonia (5) · Hungary (5) · Romania (5) · Ukraine (5) · Brazil (4)
Karen Fusaro (3) · Christian Backer Mogensen (2) · Keith Kaye (2) · A.K. Deb (1) · Anibal Calmaggi, MD (1) · Closa R Ricardo, MD PhD (1) · David Hong, MD (1) · David Melnick, MD (1) · Deepak Dewan (1) · Dharamraj Maurya (1) · Escribano J Joaquin, PhD MD (1) · Evangelos Giamarellos-Bourboulis, MD,PhD (1) · Evelyn J Ellis-Grosse, PhD (1) · Florian Wagenlehner, Prof. (1)
PMID 34593497, PMID 29339393, PMID 29339394, PMID 29339395, PMID 29486041, PMID 30270406, PMID 30786187, PMID 30861061, PMID 31433059, PMID 31843995, PMID 33332545, PMID 33565042, PMID 35041042, PMID 35388666, PMID 38354140, PMID 38780262, PMID 39638587, PMID 40827922, PMID 42134354, PMID 42829121
2015 (2), 2018 (2), 2023 (1)